Allogeneic tumors are eventually rejected by adaptive immune responses, however, little is known about how allogeneic tumors are eradicated at the early stage of tumor development. In the study, we found that NKG2DL low expressing cancer cells were developed into palpable allogeneic tumors in mice within a week after the inoculation, while NKG2DL high expressing cancer cells failed to. Artificially up-regulating NKG2DL on cancer cells with low level expressed NKG2DL by a CpG ODN resulted in the retardation and rejection of the allogeneic tumors at the early stage. The contribution of up-regulated NKG2DL to the early rejection was further confirmed by the results that the development of allogeneic tumors from cancer cells transfected with NKG2DL genes was significantly inhibited in mice at the early stage.
New research is providing a better understanding of the processes underlying cell-to-cell differences within glioblastoma tumors — a crucial finding because these differences contribute to therapy resistance.
JAX Associate Professor Jeffrey Chuang, Ph.D., has been awarded a five-year grant totaling $2,650,484 from the National Cancer Institute for research that could pave the way for the first evolution-based approaches to cancer treatment.
At JAX's new speaker event series, JAXtaposition, two scientific leaders shared how the Maine Cancer Genomics Initiative and JAX’s cutting-edge genomic testing is giving physicians access to the most advanced precision cancer care for their patients.